BD's PharMingen buy to help "speed" conversion of research products to clinical use, firm tells analysts.
This article was originally published in The Gray Sheet
Executive Summary
BD/PHARMINGEN COMBINATION TO ACCELERATE CONVERSION OF RESEARCH use reagents to clinical products by capitalizing on Becton Dickinson's expertise in developing products for clinical use and PharMingen's experience in the research market, Deborah Neff, president of BD Immunocytometry Systems, told analysts April 24 in New York City.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.